Is the business good?
How good a business is LLY?
Lilly (Eli) keeps 34% of every revenue dollar as profit after everything, against 18% for the median Drug Manufacturers - General name.
34%
Net margin · Drug Manufacturers - General median 18% · 12 months to Q2 2026
- Cash conversion
- 0.68×
Cash conversion · 0.35× a year ago · some of the reported profit has not turned into cash yet
- Share count, year on year
- −0.68%
Share count, year on year · flat: no meaningful dilution
- R&D as % of revenue
- 18%
R&D as % of revenue
Details›
- Gross margin12 months to Q2 2026
- 83%
- Net margin12 months to Q2 2026
- 34%
- Free cash flow margin
- 23%
- R&D as % of revenue
- 18%
- Revenue, trailing twelve months
- $79.7B
- Free cash flow, trailing twelve months
- $18.2B
- Net income, trailing twelve months
- $26.7B
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Drug Manufacturers - General
Ranks #1 of 16 by Smart Score